Independent Pandemic Preparedness Secretariat

The IPPS is a wholly independent entity that will serve to ensure join up between relevant states, the private sector, and global health institutions in support of the 100DM. The Secretariat will work with the G7, G20, industry and the WHO as key partners. The Secretariat was recommended by G7 Scientific Advisors, but is not a formal G7 body.

The Secretariat and the Science and Technology Expert Group will perform an annual progress review of global efforts related to the 100DM which will be used to write annual implementation reports.  These reports aim to serve as an analytical baseline to support prioritisation of effort by implementation partners and multilateral groupings. The work of the Secretariat is supported by the Wellcome Trust and the government of the United Kingdom. The secretariat is a time-limited entity which will have a progress review in 2024, and it is expected to complete its work by 2026.

Cell Matter

Steering Group

Sir Patrick Vallance

Sir Patrick Vallance

The Secretariat is led by a small Steering Group that will provide oversight and accountability for its work. Steering group members have been selected from the Secretariat’s supporting organisations (the Bill & Melinda Gates Foundation, the Wellcome Trust), three G7 Presidencies (current, incoming, and prior year’s presidency), current G20 presidency, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the two co-chairs of the Science and Technology Expert Group. The chair of the steering group will initially be Sir Patrick Vallance, UK Government Chief Scientific Adviser.

Science & Technology Expert Group (STEG)

The STEG will provide technical advice to the Secretariat on its work and galvanise support from the global scientific community on pandemic preparedness through meetings, scientific working groups, assessments, and other related activities. The STEG will provide technical input and an assurance function for the annual implementation reports across the full range of recommendations under the 100 Day MissionThe STEG will report to the Steering Group and membership of the STEG may change over time to ensure its expertise aligns with and supports priority areas of the 100 day mission. The co-chairs of the STEG will join the membership of the Steering Group to ensure dialogue between the two groups.

The IPP Secretariat is currently accepting nominations for the STEG. The group will be selected to ensure gender and regional diversity. Nominations, including self-nominations, are invited through an open process and will be assessed as individuals against the following criteria:

  • Technical expertise in disciplines such as biology, biotechnology, immunology, pharmacology, vaccinology, epidemiology, virology, molecular biology, social science, and/or data science
  • Expertise in one of the following priority areas of the mission: surveillance, research and development coordination, clinical trials and regulation, regionalised manufacturing, or financing
  • Leadership roles in academia, philanthropies, industry or international organisations
  • Insight into innovative and accessible formulations for diagnostics, therapeutics, and vaccines (for example, to optimise rollout and community engagement)
  • Management and oversight of large-scale international clinical trials
  • Knowledge of global regulatory processes

Nominations will be reviewed and 12 to 14 members will be selected by a committee of independent experts. If a nominee is not initially selected to sit on the STEG they will be invited to form part of a pool of 100 Day Mission scientific advisers whose expertise may be drawn on for future working groups, events or reports.

Nominations close on the 5th February.

Science & Technology Expert Group (STEG)